Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in January and February 2017.
Abbisko brings in $28mm via Series A
China-based Abbisko Therapeutics raised $28mm through its Series A financing to Lilly Asia Ventures, Sinopharm Capital, Jianxin Capital, and...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.
Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.
Oral RNA splicing modulator has gone into a Phase II/III trial
